| Name | Title | Contact Details |
|---|
Making Life Better for Those Living with Kidney Disease. For nearly 40 years, our mission has remained unchanged. From the patient chair side to the boardroom, this powerful yet practical principle guides our daily clinical work as well as our leadership decisions.
Well & Company™ is igniting a self care revolution, offering its community members a powerful opportunity to share daily strategies that confront significant health and lifestyle challenges including aging, weight gain, fatigue, sleeplessness, stress, and loneliness. We “Embrace the Day™,” through social selling with our engaging content, innovative products and inspired community.
Colorado Health Care Association is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
LTC Group is a Irving, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.